GleamWall
中文EN

CCCC C4 Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1662579 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY7.2%
TTM net income YoY23.5%
TTM EPS YoY62.3%
Revenue 3-yr CAGR16.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-315.9%
Net margin-282.2%
FCF margin-247.1%
EBITDA margin-311.2%

Returns

ROE-47.6%
ROA-30.5%
ROIC (approx.)-55.3%
Asset turnover0.11x

Leverage & solvency

Liabilities / assets31.2%
Debt / equity0.00x
Current ratio5.17x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-3.8%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$35.95M$35.58M
R&D expense$104.24M$110.64M
SG&A expense$36.20M$42.12M
Operating income-$115.22M-$119.61M
Pretax income-$104.87M-$105.19M
Income tax$121,000$131,000
Net income-$104.99M-$105.32M
EBITDA-$113.26M-$117.80M
EPS (basic)-1.27-1.52
EPS (diluted)-1.27-1.52
Weighted avg. shares (diluted)82.89M69.37M
Balance sheet
Cash & equivalents$74.60M$58.94M
Receivables$2.40M$3.10M
Current assets$258.11M$257.77M
PP&E, net$4.74M$5.84M
Total assets$359.07M$349.60M
Current liabilities$33.03M$45.18M
Total liabilities$102.49M$133.62M
Shareholders' equity$256.59M$215.99M
Shares outstanding96.91M70.63M
Cash flow statement
Operating cash flow-$98.69M-$65.16M
Capital expenditure$607,000$180,000
Free cash flow-$99.30M-$65.34M
Investing cash flow-$8.60M-$51.27M
Financing cash flow$126.40M$45.34M
Depreciation & amortization$1.96M$1.82M
Stock-based compensation$19.10M$29.66M
Share buybacks$193,000$194,000

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.